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The differential diagnosis of pleural effusion often requires invasive procedures. Up to 25
percent of pleural effusions can remain undiagnosed with an unclear pathogenesis. Therefore
new biological markers may increase diagnostic yield and provide better understanding of
pathogenesis of pleural effusion. We hypothesized that new ischemia biomarker, “ischemia
modified albumin (IMA)” would help in both the differentiation of the underlying etiologies
and provide a better understanding of pathogenesis of pleural effusions. This study was done
between December 2009 and September 2010 in the Department of Pulmonary Diseases of Ga-
ziantep University Hospital. One hundred and sixteen subjects with pleural effusion were
included. Pleural and blood IMA levels were measured by ELISA. The underlying etiologies of
pleural effusions were as follows: transudates (n Z 50), malignancy (n Z 32), tuberculosis
(n Z 12), pulmonary thromboembolism (n Z 6), pneumonia (n Z 16). The median pleural
IMA levels were significantly different between the groups (p < 0.000). There were no such
differences in the blood levels of IMA. The most striking difference in the median pleural
IMA levels was between transudates and exudates (7986 (25e75%, 5145e56.505) ng/mL;
3376 (25e75%, 1935e4660) ng/mL; respectively, p Z 0.000). The area under the ROC curve
was 0.837  0.038 for the cut-off level higher than 4711 ng l/mL for the differentiation of tran-
sudates from exudates (sensitivity, 82%; specificity, 78%; 95% CI, 0.76 to 0.91; p Z 0.0000). In
conclusion, the pleural IMA levels are higher in transudates compared to exudates. No such
differences were observed in blood levels of IMA suggesting that there are reasons other than
ischemia that cause an increase in pleural fluid IMA levels.
ª 2011 Elsevier Ltd. All rights reserved.42 3606060x76187; fax: þ90 342 3600663.
om (O. Dikensoy).
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Differential diagnosis of pleural effusions 1713Introduction 70 C for the further analysis. Fluid samples undergoing
Pleural effusions are among the most common clinical
problems worldwide. Although management of pleural
effusions is usually done by a pulmonologist, physicians
from all specialties may have patients with a pleural effu-
sion. They are frequently the complications of systemic
diseases. Approximately 1.5 million patients with pleural
effusion are admitted to hospitals annually in the USA.1
Clinical and radiological findings rarely yield a definitive
diagnosis. Invasive diagnostic procedures such as thoraco-
scopy or thoracotomy are needed in a significant portion of
patients with pleural effusion. Therefore, there is an
ongoing demand to discover less invasive diagnostic
methods such as pleural biomarkers in the differential
diagnosis of pleural effusions.
Ischemia modified albumin (IMA) is a relatively new
biomarker advocated in the early diagnosis of cardiac
ischemia.2 It has been suggested that IMA is a better
ischemia biomarker compared to other conventional
ischemia markers such as troponin and creatine kinase.3
There are few data available on the usage of IMA in
diseases other than cardiac ischemia.4e6 There is one
recent report that investigated the diagnostic value of IMA
measurement in pleural effusions due to cardiac failure.7
They reported that IMA levels are higher in both serum
and pleural fluid samples of subjects with cardiac failure
compared to subjects with pleural effusion due to other
etiologies. We hypothesized that IMA levels would be higher
in some of the pleural effusions due to pathologies causing
significant systemic or pleural ischemia. Therefore, we
aimed to investigate the role of IMA measurement in the
differential diagnosis of pleural effusions.
Materials and methods
This study was conducted between December 2009 and
September 2010 in the Department of Pulmonary Diseases
of Gaziantep University Hospital. All the subjects who were
personally seen or referred from other departments for
pulmonary consultation to Department of Pulmonary
Diseases were screened for pleural effusion. All subjects
who had a pulmonary effusion that needed to be tapped
were included if they signed an informed consent and there
was no contraindication for thoracentesis. The study
protocol was approved by the Ethics Committee of Gaz-
iantep University (date: 08/December/2009, number:04).
Additional blood and pleural fluid samples were collected
previously for another study conducted between November
2008 and November 2009.
Medical history was taken and physical examinations
were performed for all subjects. All the subjects had
routine blood tests, urinalysis and chest x-rays. Computed
tomography (CT) of thorax or spiral CT angiography was
performed when needed. Thoracenteses were performed
under local anesthesia with ultrasonographic guidance by
a pulmonary fellow (NC). At least 10 mL of pleural effusion
was drained. Macroscopic appearances of the pleural
effusions were recorded. Pleural fluid was collected in red-
top Vacutainer Tubes, containing no anticoagulant for IMA
measurements and centrifuged at 1,000 g at 4 C for10 min. The supernatants were then removed and frozen at
prior freezeethaw cycles were excluded. At least 10 mL of
blood was collected in red-top Vacutainer Tubes, contain-
ing no anticoagulant. Specimens were routinely centrifuged
within 2 h of collection for 10 min at 1000 g, and serum was
harvested. After routin blood tests were performed
remaining serum samples were frozen at 70 C for the IMA
analysis. Total protein, albumin, glucose, lactate dehy-
drogenase (LDH) and IMA levels were measured in both
blood and pleural effusions of all subjects. Differential cell
count, blood gas analysis, microbiological tests, adenosine
deaminase measurement, and cytological examination of
the pleural fluid were performed when needed for the
differential diagnosis. Pleural samples for the gas analyses
were obtained from the syringe used for fluid aspiration.
Medical records of all subjects were reviewed by two
physicians separately (OD and NC) before IMA analyses were
performed. Only subjects with a definitive diagnosis were
included. Discrimination between transudates and
exudates were done according to Light’s criteria.8 When
there was a discrepancy between the clinical impression
and the Light’s criteria, protein9 and albumin gradients10
were calculated for the final decision. The effusions were
defined as due to congestive heart failure (CHF) when
ejection fraction was lower than 50% with echocardiog-
raphy and the effusion regressed following treatment of
left heart failure. Echocardiograms were performed by
cardiology specialists. All the other transudative effusions
related to other conditions such as hypoproteinemia,
cirrhosis or the nephrotic syndrome were included in tran-
sudative effusions group. The malignant pleural effusions
were defined as the effusions associated with diagnosed
malignancy when either cytopathology was positive for
malignancy in the pleural samples or all the possible
reasons for the etiology of pleural effusion were excluded.
Parapneumonic effusions (PPEs) were defined as exudative
pleural effusions associated with diagnosed lung infection
other than tuberculosis when there was no other reason for
the pleural effusion. When thoracentesis yielded pus it was
called empyema and included in the PPEs group. Tubercu-
lous (TB) pleural effusions were defined as the effusions
associated with lung tuberculosis or effusions either with
high ADA levels and lymphocytic predominance or effusions
with granuloma formation in the pleural biopsy specimens.
Effusions were attributed to pulmonary thromboembolism
when the effusions were related to pulmonary thrombo-
embolism diagnosed with spiral CT angiography and the
effusions regressed following anticoagulant therapy.
Levels of IMA were measured using the commercial
Enzyme-Linked Immunosorbent Assay (ELISA) kit (Uscn Life
Science Inc. Wuhan, P.R. China) with detectable IMA
ranging from 7.8 to 500 ng/mL. The pleural samples were
diluted 1:10 with PBS and all the results were multiplied by
a factor of 10 in order to correct for the mandated dilution.
Patients who had IMA levels above the maximum level of
the kit were assigned a value of 5000 ng/ml. Patients who
IMA levels below the minimum level of the kit were
assigned a level of 7.8 ng/ml. The ELISA analyses were done
by a trained biologist (BG).
The effusions were classified into three groups as clear,
cloudy, and bloody according to their macroscopic
Table 1 Demographics of the subjects.
Etiological Groups Number (n) Age (year)a
Male Female Total Male Female Total
Malignancy 18 14 32 57.9  15.6 57.8  9.9 57.9  13.2
Transudates 29 21 50 63  16 59.8  16.9 62.8  16.1
Tuberculosis 9 3 12 44.3  19 30  11.3 44.7  20.4
PTE 1 5 6 60  25.4 54.7  12.2 56.5  15
Pneumonia 11 5 16 59.4  11.8 49.2  19 53.1  14.2
Total 68 48 116 56.6  16.3 56.4  15.3 56.5  15.8
PTE: pulmonary thromboembolism.
a Data shown as mean  standard deviation.
1714 O. Dikensoy et al.appearances. The radiological sides of the effusions were
recorded as right sided, left sided, or bilateral according to
their appearances on Chest X-rays and thorax CT findings.
The latter was obtained when necessary. The radiological
size of the effusions were defined as 1/3, 1/2 and
between 1/3 and 1/2 according the chest X-rays. The
predominant cells were defined as the largest portion of the
blood cells in the differential cell count of pleural effusions.
Statistical analyses were done using SPSS 16 software
(SPS, INC; Chicago, IL). The association between the levels
of two categorical variables was evaluated with the Chi-
square test, and the correlation between the variables was
calculated by Spearman correlation coefficient. The normal
distribution of the data was tested by the Shaphiro Wilks
test. Comparison of more than two groups was done using
One Way ANOVA unless the data was not normally distrib-
uted in which Kruskal Wallis test was done. ROC analysis
was done for the detection of a cut-off level in the differ-
entiation of transudates from exudates. When the data
is normally distributed it is shown as mean  standard
deviation (SD), otherwise it is shown as median (25e75%).
A p value <0.05 was accepted as being significant.Results
A total of 100 subjects with pleural effusion who were seen
in the pulmonary department during the study period and
additional 16 subjects from the pleural effusion pool wereTable 2 The radiological features, macroscopic appereances a
Diagnosis Radiological Size
n (%)
Radiological Side
n (%)
<1/3 1/3e1/2 >1/2 Right Left
Malignancy 12(37) 14(44) 6(19) 21(66) 9(28)
Transudates 26(52) 21(42) 3(6) 29(58) 3(6)
Tuberculosis 6(50) 5(42) 1(8) 7(58) 4(33)
PTE 0 4(67) 2(33) 0 5(83)
Pneumonia 2(13) 10(62) 4(25) 5(31) 9(56)
Total 46(40) 54(47) 16(13) 62(53) 30(26)
PTE: Pulmonary thromboembolism.included. The number of subjects in each etiologic group
and the demographics are shown in Table 1.
Thirty-two out of 116 subjects had malignant pleural
effusions. The origins of the primary tumors were as
follows: 15 lung cancers, nine malignant pleural mesothe-
liomas, and eight extrapulmonary cancers. All the malig-
nant pleural effusions were exudates. There were 50
subjects in the group of transudative effusions. Forty-one
of these transudates were due to congestive heart failure
(CHF), while the remaining nine effusions were due to
hypoalbuminemia (n Z 7), chronic renal failure (n Z 1),
and hepatic cirrhosis (n Z 1).
All the PPEs were exudates. Seven out of 16 subjects
with PPEs had empyema while the rest of the effusions in
this group were complicated parapneumonic effusion
according to criteria of the ACCP.11
The radiological features, macroscopic appearance, and
the predominant cell types of the effusions are shown in
Table 2. The blood gas analyses of the pleural and serum
samples were obtained in 53 and 26 subjects, respectively.
The mean pleural PO2 and pH were 127.7  30.5 mm-Hg
and 7.38  0.2, respectively. The mean serum PO2 and pH
were 68.1  29.8 mm-Hg and 7.42  0.06, respectively.
The comparison of pleural and serum IMA levels in
different groups is shown in Fig. 2. Pleural IMA levels were
significantly different between the different etiological
groups (p < 0.000, Fig. 2A). There were no significant
differences in themean serum IMA levels between the groups
(pZ 0.431, Fig. 2B). There was no significant difference in
serum IMA levels between transudates and exudates. Thend the predominant cell types of the pleural effusions.
Macroscopic appereance
n (%)
Predominant Cell
n (%)
Bilateral Clear Bloody Cloudy Neutro Lympho
2(6) 4(13) 11(34) 17(53) 10(59) 7(41)
18(36) 37(74) 0 13(26) 4(57) 3(43)
1(8) 5(42) 1(8) 6(50) 1(11) 8(89)
1(17) 0 4(67) 2(33) 3(75) 18(25)
2(13) 0 2(12.5) 14(87.5) 3(60) 2(40)
24(21) 46(40) 18(15) 52(45) 23(52) 21(48)
Figure 1 Roc analyses for pleural IMA, protein and LDH to
differentiate transudates from exudates (IMA, ischemia modi-
fied albumin; LDH, lactate dehyrogenase) [fx1].
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Figure 2 Pleural and Blood IMA Levels in the Groups (CA,
Cancer; TB, tuberculosis; PTE, pulmonary thromboembolism),
A) Pleural IMA levels, B) Blood IMA Levels.
Differential diagnosis of pleural effusions 1715median pleural IMA levels were significantly different
between the transudates and exudates [7986 (25e75%,
5145e56505) ng/mL; 3376 (25e75%, 1935e4660) ng/mL;
respectively, pZ 0.000)]. The area under the ROC curve for
pleural IMA was found to be 0.837  0.038 for the cut-off
level > 4711 ng/mL for the differentiation of transudates
from exudates (sensitivity, 82%; specificity, 78%; 95% CI,
0.763 to 0.912; pZ 0.0000). The area under the ROC curve
for pleural protein was found to be 0.889  0.03 for the cut-
off level > 2.83 mg/mL to differentiate exudates from
transudates (sensitivity, 86%; specificity, 64%; 95% CI, 0.83 to
0.95; pZ 0.0000) whereas it was 0.929  0.026 for pleural
LDH with a cut-off level >401 U/L to differentiate exudates
from transudates (sensitivity, 86%; specificity, 92%; 95% CI,
0.88 to 0.98; p Z 0.0000). The results of the ROC analyses
including area under the curve, sensitivity, and specificity
were all better for pleural protein and LDH to differentiate
transudates from exudates compared to pleural IMA (Fig. 1).
The median pleural IMA levels of transudates other than
those due to congestive heart failure [7259.2
(4862.5e56505) ng/mL] was also higher than exudates, but
the median levels did not differ significantly between those
in patients with heart failure and those with transudates of
other etiology (p Z 0.951). There was no significant
difference in the median IMA levels in the four exudative
groups (Table 2). The comparison of mean serum levels of
IMA showed no significant difference between transudates
due to congestive heart failure and other transudates
(44.5  22 ng/mL, 52.3  35.5 ng/mL, p Z 0.115).
There was no significant difference in pleural or serum
IMA levels between the smoker and nonsmoker subjects
(p > 0.05).
The correlation analyses were shown in Table 3. There
was a strong negative correlation between the pleural IMA
and pleural protein levels [rZ() 0.568; p Z 0.0001].
There were intermediate negative correlations betweenthe pleural IMA and pleural albumin, LDH, and pH values.
There was no significant correlation between pleural IMA
and serum PO2 or serum pH. The correlation analyses
between the serum parameters showed that there was an
intermediate negative correlation between the IMA and
protein levels whereas a weak negative correlation was
found between the IMA and albumin levels. There was no
significant correlation between serum and pleural IMA
levels (r Z 0.094; p Z 0.314).
Discussion
The IMA levels were found to be significantly different
between the pleural effusions due to different etiologies.
The pleural fluid IMA level was found to be the highest in
the transudative effusions compared to that of the other
etiologies and it was found to be the lowest in TB pleurisy.
The median IMA was significantly higher in transudates
1716 O. Dikensoy et al.compared to exudates. The ROC analysis showed that the
measurement of pleural fluid IMA levels has high sensitivity
and specifity to differentiate transudates from exudates.
Recently, the IMA has been proposed to be a more
sensitive marker to indicate ischemia especially with
coronary artery diseases compared to conventional
ischemia markers such as troponin, and creatine kinase
MB.2,3 IMA has been studied in different diseases causing
ischemic conditions such as mesenteric ischemia, skeletal
muscle ischemia, stroke and pulmonary embolism.4e6
Pleural IMA measurement was the subject in only one
study which was published recently after the present study
was completed.7 They investigated the diagnostic value of
IMA measurement in pleural and blood samples of 40
subjects including 10 subjects in each of the following
groups: cardiac failure, pulmonary embolism, para-
pneumonic effusions, and malignancy. The authors
concluded that IMA levels both in blood and pleural samples
were higher in subjects with cardiac failure compared to
other groups of patients. In the present study, the median
pleural IMA levels were higher in the transudative pleural
effusions compared to those in the pleural effusions due to
malignancy, infections and pulmonary embolism. The
median levels with congestive heart failure were not
significantly different than the median levels with non-
cardiac transudates. In contrast to study done by Ozsu
et al.7 the mean serum levels of IMA were not different
between the transudates and exudates.
The methods used to measure IMA levels were different
in the two studies. Ozsu et al. used a cobalt binding assay in
contrast to the ELISA used in the present study. Albumin
Cobalt Binding Test is based on observations that the
binding of Co(II) is reduced in serum from patients with the
acute coronary syndrome.2 The NH2 terminus of albumin
has the capacity of binding transition metals Co(II), Cu(II),
and Ni(II).12e14 Conditions that can alter albumin’s N-
terminal region, and therefore albumin metal binding, can
occur within minutes of an ischemic event via induced
endothelial and extracellular hypoxia, acidosis, free radical
injury, and sodium and calcium pump disruptions.12e14 This
effect on albumin could be detectable up to 6 h after the
ischemic event.13,14 ELISA measures the whole portion of
albumin that has lost its ability to bind any metals. We
suggest there are some other factors, locally, associated
with increased production of IMA, or the decreased elimi-
nation of IMA from the pleural space that explain why theTable 3 Spearman Rank test for the correlation of the variable
Pleural fluid IMA
P value Correlation coefficient
Protein 0.0001 0.568
LDH 0.001 0.350
Albumin 0.0001 0.438
pH 0.003 0.399
PO2 0.748 0.045
Pleural IMA
LDH: lactate dehyrogenase, IMA: ischemia modified albumin.
Bold values represents the differences were significant at a P < 0.05levels are so much higher in the pleural fluid than in the
serum. These hypotheses need to be investigated.
The ROC analysis showed that pleural IMA levels
>4711 ng/mL has a sensitivity of 82% and specifity of 78% to
differentiate transudates from exudates. Although this
study was not intended to investigate the efficacy of IMA to
differentiate transudates from exudates, this finding is
interesting for certain aspects. Most biological or
biochemical markers tend to be higher in exudates
compared to transudates. Recently, it has been shown that
N-terminal pro brain natriuretic peptide (NT-proBNP) levels
were higher in transudates due to congestive heart failure
compared to exudates.15,16 To the best of our knowledge,
pleural IMA is the second marker found to be higher in
transudates compared to exudates. On the other hand, the
pleural IMA levels were found to be increased in all the
transudates including those due to noncardiogenic pathol-
ogies. However, pleural NT-proBNP levels are reported to
be higher only in transudates due to heart failure.
The ROC analyses for pleural protein and LDH levels to
differentiate transudates from exudates showed that the
area under the curve, sensitivity and specifity for these
measurements were better than pleural IMA levels.
Previously it has been suggested that the pleural
permeability for many parameters is closely related with
pleural protein level.17 The present study shows that
pleural IMA levels had negative strong correlation with
pleural protein levels. This sounds contradictory to previous
findings, but is probably related to the fact that patients
with CHF have lower pleural fluid protein levels than do
patients with exudative pleural effusion. However, It
should be noted that only a small percentage of the
albumin is IMA. In addition the pleural fluid IMA levels were
markedly higher than the simultaneously obtained serum
IMA levels. This strongly suggests that IMA is being gener-
ated in the pleural surfaces or the pleural fluid. There were
also negative intermediate correlations between pleural
IMA levels and pleural pH and albumin levels. Interestingly
there was no such correlation between pleural IMA levels
and pleural PO2. This is difficult to explain on the basis of
present data that suggests that IMA increases following
hypoxemia.14 However, there is no previous study that
investigated the local factors associated with increase in
IMA levels. Findings of the present study suggest there
might be some local factors causing significant local
increase in pleural IMA levels.s.
Serum IMA
(r) P value Correlation coefficient (r)
0.003 0.304
0.174 0.143
0.011 0.267
0.148 0.198
0.209 0.174
0.314 0.094
.
Differential diagnosis of pleural effusions 1717There are certain limitations to the present study. The
number of the subjects is relatively small especially in
parapneumonic effusion, tuberculosis, and pulmonary
thromboembolism groups. Also the blood gas analyses were
not done on all the samples. The pulmonary function tests
would have to be done to be aware of pulmonary comor-
bidities that might cause systemic hypoxia, acidosis or
oxidative stress.
In conclusion, the pleural IMA levels are increased more
than serum levels in all the conditions. The pleural IMA
level is highest in transudative and lowest in tuberculosis
pleurisy. The measurement of pleural IMA has a high
sensitivity and specifity to differentiate transudates from
exudates, although it is not superior to Light’s criteria.Funding
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